Skip to content

BYAKKO-ROSE study

A multi-center, randomized control study of combination therapy of Byakkokaninjinto and Metronidazole gel for hot flashes associated with rosacea. (BYAKKO-ROSE)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCTs031240745
Enrollment
50
Registered
2025-03-26
Start date
2025-06-16
Completion date
Unknown
Last updated
2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rosacea Rosacea

Interventions

The enrolled subjects will be randomized to either Byakkokaninjinto or control group. Both groups will receive metronidazole gel twice a day for 12 weeks. Byakkokaninjinto group will also receive 6.0g

Sponsors

Wook-Kang Huh
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Patients over 18 years old at the time of consent acquisition 2) Patients diagnosed with rosacea of erythema severity 2 (mild) or higher 3) Patients with hot flashes of NRS 5 (moderate) or higher 4) Patients who have been fully informed about their participation in this study, and who have given written consent of their own free will based on full understanding.

Exclusion criteria

Exclusion criteria: 1) Patients who have serious heart, liver, renal, pulmonary, hematological, or other diseases that make them unsuitable to participate in the study 2) Patients with organic diseases of the brain and spinal cord (excluding patients with brain and spinal cord tumors) 3) Patients with a history of hypersensitivity to any component of the study drug 4) Patients who are scheduled to undergo chemical peels or laser therapy during the study period 5) Pregnant or possibly pregnant during the study period or breast-feeding 6) Patients who have been taking Kampo medicines within 1 weeks from the start of administration. 7) Patients who have been taking metronidazole gel for skin disease within 1 month from the start of administration. 8) Patients diagnosed with rosacea-like dermatitis (perioral dermatitis, steroid-induced rosacea) at the time of obtaining consent 9) Patients who are participating in another clinical trial or have participated in other clinical trials within 1 month from the time of obtaining consent 10) Other subjects deemed inappropriate as research subjects by the principal investigator (or subinvestigator)

Design outcomes

Primary

MeasureTime frame
Amount of change in facial hot flashes (NRS) before and after treatment (baseline to 12 weeks)

Secondary

MeasureTime frame
Evaluate the amount of change before and after treatment (from start of study to 2, 4, 8, 12 weeks). 1) Hot flashes on the face (NRS) 2) Facial skin temperature (quantitative using a thermal imaging camera with image analysis software) 3) Dry mouth (NRS) 4) Dryness of the face (NRS) 5) Erythema severity 6) Facial redness (quantified by image analysis software) 7) Number of inflammatory rashes 8) Skindex-16

Contacts

Public ContactHuh Wook-Kang

Dr. Huh's Dermatology Clinic

wookkang12@hotmail.com+81-86-426-1210

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Sep 19, 2026